Fertility startup Inito has raised US$29m in Series B to scale its at-home diagnostics platform and develop AI-designed antibodies.
The funding round was led by Bertelsmann India Investments and Fireside Ventures, bringing Inito’s total funding to around US$45m.
The company previously raised US$6m led by Fireside Ventures and US$9m from Y Combinator, former Nurx chief executive Varsha Rao, and a dozen physicians and family offices.
The company said the investment will help it evolve from a fertility tracker into a broader hormone and at-home health diagnostics platform.
Inito allows women to measure oestrogen, LH, PdG and follicle-stimulating hormone (FSH, which supports egg development) on a single test strip.
The company’s AI models interpret these levels to reveal hormone patterns, track fertile days and confirm ovulation.
Varun Venkatesan, Inito co-founder and chief technology officer, said: “We predict how proteins fold in 3D, design synthetic antibodies using AI, and test millions of variants virtually before making a single one in the lab.
“This produces antibodies that are far more sensitive, consistent, and stable than anything developed through traditional methods.”
The startup said it has analysed more than 30 million fertility hormone data points since 2021.
Inito said it is using the new funding to invest in AI-engineered antibodies (proteins that bind to target molecules), which it claims will allow new types of tests and improve the accuracy of existing ones.
In diagnostic tests, antibodies bind to targets such as oestrogen or testosterone to produce a signal.
Traditional antibodies are grown inside animals and then screened manually in the lab.
Aayush Rai, Inito co-founder and chief executive, said: “The real vision is bigger than adding new tests. The endgame is to redefine diagnostics altogether.
“If you want to understand what’s happening inside your body at every life stage and health need, you shouldn’t be limited by clinic appointments, lab schedules, or rigid testing systems.
“You should be able to measure, track, and get insights about your body from home, with lab-grade confidence.”
The company plans to expand beyond fertility, with its reader and app set to power tests for pregnancy, menopause and broader at-home health monitoring.
